Enumeral Biomedical Holdings Inc

Enumeral Biomedical — Corporate Update (November 2015)

15 slides from Enumeral Biomedical's corporate update, Nov 3, 2015

  1. Slide 1: PD-1 Program Update: Differentiated Anti-PD-1 Antibody Elicits Higher T Cell Activation

    Enumeral PD - 1 Program Update: Differentiated Anti - PD - 1 Antibody Elicits Higher T Cell Activation in Ex Vivo Human Assays than a Currently Marketed Anti - PD - 1 Antibody November 3, 2015

  2. Slide 2: Background

    Background • Enumeral uses a unique single cell technology platform and approach to identify functionally differentiated antibody candidates – Enumeral has identified two distinct classes of anti - PD - 1 antibodies with distinct modes of binding to PD - 1 – Both classes demonstrate enhancement of T

  3. Slide 3: Enumeral's Approach to Developing Differentiated Antibodies Starts with Diversity

    Enumeral’s Approach to Developing Differentiated Antibodies Starts with Diversity • Enumeral antibody discovery results in exceptional diversity* • Potential for strong IP position • Breadth of diversity: keys to unlocking the target physiology • Multiple potential program opportunities OPDIVO® KEYT

  4. Slide 4: Enumeral Program

    Enumeral PD - 1 Program • Enumeral has identified a novel potentially allosteric anti - PD1 antagonist (ENUM 244C8) displaying the following properties: – Reversal of PD - L1 - dependent immunosuppression – Binding to PD - 1 via a novel epitope – Increased levels of T cell activation in cell - based

  5. Slide 5: ENUM 244C8 Binding to PD-1 Does Not Displace PD-L1

    ENUM 244C8 Binding to PD - 1 Does Not Displace PD - L1 Positive control EH12.2H7 Negative control mIgG1K 388D4 244C8 ENUM 388D4, but not ENUM 244C8, blocks the binding of soluble PD - L1 to cells expressing PD1 . HEK293 cells expressing PD1 were incubated with 10ug/mL of isotype, EH12.2H7, 388D4 or

  6. Slide 6: Methods

    Ex Vivo Reversal of TIL Exhaustion: Methods • NSCLC samples from staging surgeries were analyzed within 24 hours of collection • Flow cytometry analyzed extent of T cell infiltration and co - expression of immunomodulatory receptors • Cells were incubated with anti - CD3/anti - CD28 antibodies for 2

  7. Slide 7: Example Flow Cytometry Analysis

    Ex Vivo Reversal of TIL Exhaustion: Example Flow Cytometry Analysis 7 NSCLC WD36444 contains 14% T cells

  8. Slide 8: Co-expression of Immunomodulatory Receptors

    Ex Vivo Reversal of TIL Exhaustion: Co - expression of Immunomodulatory Receptors • WD36444 CD4+ and CD8+ TILs express exhaustion markers (IMRs) • PD - 1 expressed on 55% of CD4 cells and 75% of CD8 cells • ‘IMR X’ expressed 5.5% of CD4 cells and 13% of CD8 cells 8 CD4 cells CD8 cells PD - 1 Immunom

  9. Slide 9: Variability Across Patients

    Ex Vivo Reversal of TIL Exhaustion: Variability Across Patients 9 Tumor Identifier % EpCAM - CD45+ %CD3+ %CD4 + PD1 + %CD8 + PD1 + WD - 36444* 25.7 14 55 75 WD - 36571 10.3 6.3 47 64 WD - 36686* 21.6 17 55 84 WD - 36790* 16.8 10.4 38 68 WD - 36904 12.8 7 63 72 M115801A2 3.4 2.9 79 84 WD - 36923 1.6

  10. Slide 10: Experimental Questions

    Ex Vivo Reversal of TIL Exhaustion: Experimental Questions • Tumor biopsy from n=9 patients found to harbor TILs that express exhaustion markers including PD - 1. 1. What is the activity of the T cells following activation? 2. Is cellular activity modified by the addition of an anti - PD1 antibody?

  11. Slide 11: PD-1 Blockade Observed Restoring Function to T cells Derived From Human Lung Biopsy

    Ex Vivo Reversal of TIL Exhaustion: PD - 1 B lockade Observed Restoring F unction to T cells Derived F rom H uman L ung B iopsy Functional modification of TILs with PD - 1 blockade. Tumor cells containing 14% lymphocytes were activated in the presence of anti - CD3+anti - CD28 and the indicated anti

  12. Slide 12: PD-1 Blockade Observed Restoring Function to T cells (Continued)

    Ex Vivo Reversal of TIL Exhaustion: PD - 1 Blockade Observed Restoring Function to T cells Derived From Human Lung Biopsy ( C ontinued) 12 I s o t y p e C o n t r o l N i v o l u m a b ( 1 0 u g / m L ) 2 4 4 C 8 - 2 ( 1 0 u g / m L ) 0 5 10 15 20 F o l d I n d u c t i o n I F N -  ( r e l a t i v

  13. Slide 13: PD-1 Blockade Observed Restoring Function to T cells (Continued)

    13 Functional modification of Tumor infiltrating lymphocytes with PD - 1 blockade. 3e5 WD36790 tumor cells containing 10 % lymphocytes were activated in the presence of anti - CD3+anti - CD28 and the indicated antibodies: 244C8 - 2 (at two different concentrations), Nivolumab S228P ( Invivogen ). Ti

  14. Slide 14: Conclusions

    Conclusions • ENUM 244C8 is a humanized anti - PD - 1 antibody that binds PD - 1 but does not compete with PD - L1 and thus represents a pharmacologically novel class of anti - PD - 1 therapeutic. • Following incubation with anti - CD3/anti - CD28 antibodies activation of NSCLC tumor - derived T cel

  15. Slide 15: The Power of Human

    THE POWER of HUMAN™

Enumeral Biomedical Holdings — Corporate Update (November 2015) on 6ix